No Data
No Data
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $207
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
Positive Outlook for Jazz Pharmaceuticals Following Ziihera Approval
Jazz Pharmaceuticals Analyst Ratings
Sector Update: Health Care
No Data
No Data